ISSN: 2278-0238

Revista Internacional de Pesquisa e Desenvolvimento em Farmácia e Ciências da Vida

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

In - Vitro Drug Interaction between Tulsi and Glimepride

Dr. Yadav Swati

The study was designed to determine the interaction of O. sanctum, an herbal drug used in many herbal formulations for hypoglycemic activity with Glimepiride, a sulfonylurea (SU) derivative, widely used in the treatment of type-2 diabetes, in diabetic rats.Whole study was divided into four phases in which hypoglycaemic activity with single doses of O. sanctum and glimeperide was established in single day study and repeated dose treatment of O. sanctum (7 days) followed by a single dose of glimeperide on 8th day was also established. Further the interaction between the two drugs was studied in both single and repeated treatment, i.e., the effect of single and glimeperide repeated doses treatment on O. sanctum. All the results were analysed by one way ANOVA followed by Dunnett’s‘t’ test. Rats were administered with streptozotocin for inducing diabetes and left for 2 weeks to stabilize blood glucose levels. Various doses of O. sanctum (100, 200 and 400 mg/kg) and glimeperide (½ TD, TD and 2 TD) upon single dose treatment of each in different groups of diabetic rats produced a dose dependent decrease in blood glucose levels. The maximum reduction in serum glucose was observed at 6th h in all the groups. Single dose of O. sanctum prolonged the effect of glimepiride from 4th to 6th h without any hypoglycemic convulsions.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.